| Name | Title | Contact Details |
|---|---|---|
Mike Tarpley |
Vice President and Chief Technology Officer | Profile |
ValenTx was founded with the goal of treating some of the most pervasive health problems of our time: obesity and obesity-related metabolic disorders such as type-2 diabetes and hypertension. Our approach is to create a non-surgical, endoluminal bypass device that builds on the success of established medical interventions, resulting in a highly effective and least-invasive therapy. Current treatments for these diseases include surgery, pharmacology, and medically supervised lifestyle management. The risks, costs, and in some cases poor efficacy of these treatments have hampered their broad adoption by patients, physicians, and payers alike. A truly unmet clinical need exists for a therapy that can deliver the efficacy obtained through surgery, but without the risks and costs associated with surgical intervention. The ValenTx endoluminal bypass therapy mimics the attributes of a Roux-en-Y gastric bypass and is implanted through a non-surgical, endoscopic procedure. This procedure does not require gastric stapling or permanent changes to the patient`s anatomy. The device is removable, replaceable and designed so that the physician could change the therapeutic profile, thereby optimizing the treatment towards the individual patient`s needs. ValenTx has developed a strong intellectual property portfolio, which lies at the foundation of this therapy. The company has successfully conducted a series of clinical studies demonstrating the viability, safety, and efficacy of the therapy.
Minnetronix, Inc. is a Saint Paul, MN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Lumenis, Inc. is one of the leading companies in the Healthcare, Pharmaceuticals, and Biotech sector.
Microbot Medical was founded with the vision of pioneering Micro Invasive Surgery, transforming one of the biggest trends in healthcare - Minimally Invasive Surgery (estimated to be close to $20B by 2015); the company will provide transformational micro invasive technologies with the accuracy of robots and automated instruments to assist physicians in targeting the disease site with exquisite precision. Microbot will solve one of the largest unmet needs in the medical field, where morbidity as a result of surgery is more frequently due to trauma involved in gaining access to the area to perform the intended procedure rather than from the procedure itself. Through its unique platforms, Microbot will reach multiple surgical spaces, capitalizing on the fact that minimally invasive techniques have been applied to most of the surgical specialties. Microbot`s ViRob platform is an Autonomous Advancing Micro Robot (AAMR), less then 1mm in diameter, which has the ability to advance (forward/backward) within cavities/lumens (such as the typical human body`s veins and arteries). The TipCat platform is a self-propelled, flexible, see & treats endoscope/catheter. It is comprised of a series of interconnected balloons that provide forward and backward motion while allowing for a working channel to be available during the procedure. In developing its platforms, the company is focusing on multi-disciplinary platform of products.
Jacobsen Real-Time X-Ray Mchy is a Brampton, ON-based company in the Healthcare, Pharmaceuticals, and Biotech sector.